Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Theseus Pharmaceuticals, Inc. THRX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Theseus Pharmaceuticals, Inc. (THRX) is a Biotechnology company in the Healthcare sector, currently trading at $4.07. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $47M (loss), growing at -89%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $208M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 17.79 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $222M.

Analyst outlook: 8 / 12 analysts rate THRX as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

THRX SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — THRX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
THRX: +0%/yr revenue is, -89%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet THRX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 17.79 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
THRX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 8 / 12 analysts rate THRX as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.05-12.37
Volume677.69K
Avg Volume (30D)849.6K
Market Cap$181.5M
Beta (1Y)3.98
Share Statistics
EPS (TTM)-1.22
Shares Outstanding$38.49M
IPO Date2021-10-07
Employees38
CEOIain D. Dukes DPHIL,
Financial Highlights & Ratios
Gross Profit$-438K
EBITDA$-54.09M
Net Income$-47.08M
Operating Income$-54.09M
Total Cash$197.98M
Total Debt$3.98M
Net Debt$-90.63M
Total Assets$222.45M
Price / Earnings (P/E)-3.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering12
Buy 67% Hold 33% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS88369M1018

Price Chart

Track all markets on TradingView
THRX
Theseus Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.05 52WK RANGE 12.37

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 RCUS
RCUS
Arcus Biosciences, Inc.
$23.01
+2.77%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message